The Central Region of HDM2 Provides a Second Binding Site for P53

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2006 Jan 25

PMID 16432196

Citations 70

Authors

Grace W Yu

Stefan Rudiger

Dmitry Veprintsev

Stefan Freund

M Rosario Fernandez-Fernandez

Alan R Fersht

Affiliations

Soon will be listed here.

Abstract

HDM2 is a negative regulator of p53 that inhibits its transcriptional activity and subjects it to degradation by an E3 ligase activity. The primary binding site for HDM2 on p53 is located in its N-terminal domain. A second site on the p53 core domain (p53C) binds to an unidentified site in HDM2. We found that this site is in its acidic domain and part of the zinc finger domain by examining the interaction of full-length and domain constructs of p53 with the N-terminal region of HDM2 and peptide arrays derived from the full-length protein. NMR spectroscopy showed that peptides derived from this region of HDM2 bound to residues in the specific DNA-binding site of p53C. The peptides were displaced from the site by gadd45 sequence-specific DNA. Phosphorylation of single amino acids in the central domain of HDM2 did not abolish the interaction between the HDM2-derived peptides and p53C. We speculate that this second binding site helps in stabilizing the interaction between HDM2 and p53 during p53 degradation.

Citing Articles

Modulating the p53-MDM2 pathway: the therapeutic potential of natural compounds in cancer treatment.

Ramli I, Cheriet T, Posadino A, Giordo R, Fenu G, Chukwuemeka Nwachukwu K EXCLI J. 2025; 23:1397-1439.

PMID: 39764218 PMC: 11701300. DOI: 10.17179/excli2024-7791.

New insights into cancer: MDM2 binds to the citrullinating enzyme PADI4.

Araujo-Abad S, Rizzuti B, Villamarin-Ortiz A, Pantoja-Uceda D, Moreno-Gonzalez C, Abian O Protein Sci. 2023; 32(8):e4723.

PMID: 37409874 PMC: 10364586. DOI: 10.1002/pro.4723.

Transcriptional regulation of INK4/ARF locus by cis and trans mechanisms.

Farooq U, Notani D Front Cell Dev Biol. 2022; 10:948351.

PMID: 36158211 PMC: 9500187. DOI: 10.3389/fcell.2022.948351.

Bivalent binding of p14ARF to MDM2 RING and acidic domains inhibits E3 ligase function.

Kowalczyk D, Nakasone M, Smith B, Huang D Life Sci Alliance. 2022; 5(12).

PMID: 35944929 PMC: 9366199. DOI: 10.26508/lsa.202201472.

It's Getting Complicated-A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy.

Kung C, Weber J Front Cell Dev Biol. 2022; 10:818744.

PMID: 35155432 PMC: 8833255. DOI: 10.3389/fcell.2022.818744.

References

Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K . The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J Biol Chem. 2004; 279(51):53317-22. DOI: 10.1074/jbc.M406062200. View

Roth J, Dobbelstein M, FREEDMAN D, Shenk T, Levine A . Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 1998; 17(2):554-64. PMC: 1170405. DOI: 10.1093/emboj/17.2.554. View

Friedler A, Veprintsev D, Rutherford T, von Glos K, Fersht A . Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. J Biol Chem. 2004; 280(9):8051-9. DOI: 10.1074/jbc.M411176200. View

Fernandez-Fernandez M, Veprintsev D, Fersht A . Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci U S A. 2005; 102(13):4735-40. PMC: 555715. DOI: 10.1073/pnas.0501459102. View

Yu G, Allen M, Andreeva A, Fersht A, Bycroft M . Solution structure of the C4 zinc finger domain of HDM2. Protein Sci. 2005; 15(2):384-9. PMC: 2242465. DOI: 10.1110/ps.051927306. View

Kawai H, Wiederschain D, Yuan Z . Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol. 2003; 23(14):4939-47. PMC: 162226. DOI: 10.1128/MCB.23.14.4939-4947.2003. View

Dawson R, Muller L, Dehner A, Klein C, Kessler H, Buchner J . The N-terminal domain of p53 is natively unfolded. J Mol Biol. 2003; 332(5):1131-41. DOI: 10.1016/j.jmb.2003.08.008. View

Zhang Y, White Wolf G, Bhat K, Jin A, Allio T, Burkhart W . Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 2003; 23(23):8902-12. PMC: 262682. DOI: 10.1128/MCB.23.23.8902-8912.2003. View

Joerger A, Allen M, Fersht A . Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem. 2003; 279(2):1291-6. DOI: 10.1074/jbc.M309732200. View

10.

Meek D, Knippschild U . Posttranslational modification of MDM2. Mol Cancer Res. 2004; 1(14):1017-26. View

11.

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

12.

Jin A, Itahana K, Okeefe K, Zhang Y . Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol. 2004; 24(17):7669-80. PMC: 506972. DOI: 10.1128/MCB.24.17.7669-7680.2004. View

13.

Dai M, Lu H . Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem. 2004; 279(43):44475-82. DOI: 10.1074/jbc.M403722200. View

14.

Wiseman T, Williston S, Brandts J, Lin L . Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal Biochem. 1989; 179(1):131-7. DOI: 10.1016/0003-2697(89)90213-3. View

15.

Lane D . Cancer. p53, guardian of the genome. Nature. 1992; 358(6381):15-6. DOI: 10.1038/358015a0. View

16.

Momand J, Zambetti G, Olson D, George D, Levine A . The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69(7):1237-45. DOI: 10.1016/0092-8674(92)90644-r. View

17.

Cooper A, Johnson C . Isothermal titration microcalorimetry. Methods Mol Biol. 1994; 22:137-50. DOI: 10.1385/0-89603-232-9:137. View

18.

Kussie P, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine A . Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996; 274(5289):948-53. DOI: 10.1126/science.274.5289.948. View

19.

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

20.

Rudiger S, Germeroth L, Schneider-Mergener J, Bukau B . Substrate specificity of the DnaK chaperone determined by screening cellulose-bound peptide libraries. EMBO J. 1997; 16(7):1501-7. PMC: 1169754. DOI: 10.1093/emboj/16.7.1501. View